Literature DB >> 12849298

Immunotherapy in autoimmune neuromuscular disorders.

Ralf Gold1, Marinos C Dalakas, Klaus V Toyka.   

Abstract

Important progress has been made in our understanding of the cellular and molecular processes underlying autoimmune neuromuscular diseases that has led us to identify targets for rational therapeutic intervention. Although antigen-specific immunotherapy is not yet available, old and new immunomodulatory treatments, alone or in combination, provide effective immunotherapy for most autoimmune disorders. In parallel, the achievements of molecular medicine provide more specific yet largely experimental therapeutic tools that need to be tested in the human diseases. Here we review the principles and targets of immunotherapy for autoimmune neuromuscular disorders, address applications and practical guidelines, and give an outlook on future developments.

Entities:  

Mesh:

Year:  2003        PMID: 12849298     DOI: 10.1016/s1474-4422(03)00264-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  10 in total

1.  Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

2.  Progress in the treatment of myasthenia gravis.

Authors:  Ralf Gold; Reinhard Hohlfeld; Klaus V Toyka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 3.  Therapy of immune neuropathies with intravenous immunoglobulins.

Authors:  Ralf Gold; Bernd C Kieseier
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 4.  [Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy].

Authors:  R Gold; A Bayas; K V Toyka
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 5.  Treatment of inflammatory myopathies.

Authors:  A C Cordeiro; D A Isenberg
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

6.  Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients.

Authors:  Nurcan Üçeyler; Anna Geng; Karlheinz Reiners; Klaus V Toyka; Claudia Sommer
Journal:  J Neurol       Date:  2015-06-20       Impact factor: 4.849

Review 7.  Current and future standards in treatment of myasthenia gravis.

Authors:  Ralf Gold; Christiane Schneider-Gold
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis.

Authors:  Jie Luo; Jon Lindstrom
Journal:  J Immunol       Date:  2014-10-06       Impact factor: 5.422

Review 9.  Future perspectives in target-specific immunotherapies of myasthenia gravis.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 10.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.